Work

The novel boron-based carbonic anhydrase IX and XII inhibitor AM_DB induces cytotoxic effects and enhances the response of ovarian cancer cells to carboplatin

Year: 2026
Type: article
Abstract: Carbonic anhydrases IX and XII have become promising therapeutic targets in ovarian cancer, the deadliest gynecological malignancy. In this study, the boron-containing compound AM_DB was synthesized and tested for its ability to inhibit carbonic anhydrases. Structural analysis allowed us to understand its binding interactions within the enzyme active site. The in vitro anti-tumor potential of AM_DB, both alone and in combination with carboplatin, was evaluated in the SKOV-3, Caov-3, and OVCAR-3 cell lines. AM_DB decreased cell viability in a dose-dependent manner, especially in SKOV-3 cells, caused G2/M arrest, and elevated ROS production without inducing apoptosis. Notably, AM_DB increased carboplatin’s cytotoxic effects under hypoxia, linked to cytoskeletal disruption and reduced colony formation. Importantly, AM_DB showed no hemolytic activity. Although a comparable reduction in viability was observed in CCD-18Co and ovarian cancer cell lines, overall viability remained around 80%, indicating that AM_DB does not induce pronounced cytotoxic effects in non-tumor cells under the tested conditions. Overall, these results support the importance of targeting hCA IX and hCA XII and highlight AM_DB as a promising adjunct to standard chemotherapy for ovarian cancer.
Language: English
Open Access status: gold
Estimated APC paid: $3,290
OpenAlex ID: W7237364687
FWCI:
Cites:
Cited by:
Related to: